CALGARY, AB, Nov. 18, 2025 /CNW/ - Nanalysis Scientific Corp. ("the Company", (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR instruments and imaging technology and services for industrial and research applications announces that on Monday, November 24th, 2025, the Company will put out a press release at the market close and Chief Executive Officer Sean Krakiwsky and Chief Financial Officer Randall McRae will host a conference call at 4:15 P.M. Eastern Time to discuss the results for the quarter ended September 30, 2025.
Investors interested in participating in the live call can join through Zoom. Details provided below.
Join Zoom Meeting: https://us02web.zoom.us/j/84202060177
Meeting ID: 842 0206 0177
One tap mobile
+16469313860,,84202060177# US
+16694449171,,84202060177# US
The webcast will be archived on the Company's investor relations webpage for at least 90 days.
About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:1N1)
Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.
Notice regarding Forward Looking Statements and Legal Disclaimer
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

| Last Trade: | C$0.18 |
| Daily Volume: | 6,000 |
| Market Cap: | C$20.090M |
November 24, 2025 October 07, 2025 August 28, 2025 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load